VILYA

VILYAVILYA
VILYA

VILYA

AI-powered platform for designing novel molecular structures for new medicines.

Website
DR 4.42022Active47San Francisco, United States
Rate
Advertise here

About

Vilya pioneers computational drug design, creating entirely new de novo macrocycles inspired by biology and designed using AI. Their platform generates, predicts, and validates these molecules in silico, aiming to develop orally bioavailable therapies that combine the selectivity of biologics with the convenience of pills. Vilya serves the pharmaceutical and biotechnology industries by advancing a new class of medicines for previously untreatable diseases.
Frequently asked

What does VILYA do?

Vilya pioneers computational drug design, creating entirely new de novo macrocycles inspired by biology and designed using AI. Their platform generates, predicts, and validates these molecules in silico, aiming to develop orally bioavailable therapies that combine the selectivity of biologics with the convenience of pills. Vilya serves the pharmaceutical and biotechnology industries by advancing a new class of medicines for previously untreatable diseases.

What is VILYA's valuation?

StartupHub estimates VILYA's effective valuation at $463.9M (range $302.5M to $726.0M, 13% confidence), based on comparable companies in the sector.

How much funding has VILYA raised?

VILYA has raised a total of $121M in funding. The most recent round on record is Series A.

Where is VILYA headquartered?

VILYA is headquartered in San Francisco, United States.

When was VILYA founded?

VILYA was founded in 2022.

What industry does VILYA operate in?

VILYA operates in BIO + LIFE SCIENCES, Biotech, Drug Discovery, Genomics, AI-Driven Protein Design, HealthTech.

How many employees does VILYA have?

VILYA has approximately 47 people on record.

HEADCOUNT
47
DOMAIN RATING
4.4
Comments

No comments yet. Be the first to share your take.